230 related articles for article (PubMed ID: 36216486)
1. SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection.
Rastogi T; Girerd N
Heart Fail Clin; 2022 Oct; 18(4):561-577. PubMed ID: 36216486
[TBL] [Abstract][Full Text] [Related]
2. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential.
Brito D; Bettencourt P; Carvalho D; Ferreira J; Fontes-Carvalho R; Franco F; Moura B; Silva-Cardoso JC; de Melo RT; Fonseca C
Cardiovasc Drugs Ther; 2020 Jun; 34(3):419-436. PubMed ID: 32350793
[TBL] [Abstract][Full Text] [Related]
4. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
[TBL] [Abstract][Full Text] [Related]
5. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
Green JB; McCullough PA
Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
[TBL] [Abstract][Full Text] [Related]
6. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
Aguilar-Gallardo JS; Correa A; Contreras JP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
[TBL] [Abstract][Full Text] [Related]
7. Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction.
Abdelhamid M; Kandil H; Hassanin M; Shaheen S; Sobhy M; ElEtreby A; Hasan-Ali H; Mahfouz H; Nasr G; Shawky I; Emil S; ElSetiha M; Hasssan M; Sadek Y; Karim MA; Asham A; Ghaleb M; Samir A; Shokry K
ESC Heart Fail; 2022 Apr; 9(2):800-811. PubMed ID: 35118822
[TBL] [Abstract][Full Text] [Related]
8. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
O'Meara E; Verma S
Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
[TBL] [Abstract][Full Text] [Related]
9. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
10. [Serendipity of sodium-glucose co-transporter 2 inhibitors: a new paradigm in the management of heart failure with reduced ejection fraction].
Rosano G; Iacoviello M; Filardi PP
G Ital Cardiol (Rome); 2021 Apr; 22(4):277-283. PubMed ID: 33783447
[TBL] [Abstract][Full Text] [Related]
11. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
Johansen ME; Argyropoulos C
Clin Cardiol; 2020 Dec; 43(12):1376-1387. PubMed ID: 33165977
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction.
Wood N; Straw S; Cheng CW; Hirata Y; Pereira MG; Gallagher H; Egginton S; Ogawa W; Wheatcroft SB; Witte KK; Roberts LD; Bowen TS
Eur J Heart Fail; 2024 Apr; 26(4):925-935. PubMed ID: 38468429
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of SGLT-2 inhibitors in heart failure.
Velliou M; Polyzogopoulou E; Ventoulis I; Parissis J
Expert Rev Clin Pharmacol; 2023 Feb; 16(2):149-160. PubMed ID: 36701817
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat.
Girerd N; Zannad F
J Intern Med; 2023 May; 293(5):550-558. PubMed ID: 36871279
[TBL] [Abstract][Full Text] [Related]
15. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
Starr JA; Pinner NA; Lisenby KM; Osmonson A
Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578
[TBL] [Abstract][Full Text] [Related]
16. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction.
Kim HM; Hwang IC; Choi W; Yoon YE; Cho GY
Sci Rep; 2021 Nov; 11(1):22342. PubMed ID: 34785723
[TBL] [Abstract][Full Text] [Related]
18. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
[No Abstract] [Full Text] [Related]
19. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
[TBL] [Abstract][Full Text] [Related]
20. Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction.
Ostrominski JW; Vaduganathan M
Am J Med; 2024 Feb; 137(2S):S9-S24. PubMed ID: 37160196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
